Unknown‑primary neuroendocrine neoplasms diagnosed by short‑acting somatostatin test: Case series in one institution
Authors:
Open Access
- 16 November 2022
- journal article
- research article
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 25 (1) , 1-5
Abstract
Neuroendocrine neoplasms (NENs) are a rare heterogeneous group of neoplasms that arise from neuroendocrine cells. Unknown‑primary NENs (UP‑NENs) are particularly challenging to diagnose and treat. Techniques such as immunohistochemical stains, functional imaging studies, and molecular cancer classifier assays may help clinicians identify the origin of a tumor. However, numerous medical facilities lack the necessary medical equipment, such as functional imaging scanning, to provide patients with a complete primary tumor survey. Even these tests are not enough to determine the original tumor in some cases. The present case series described the diagnosis and treatment outcomes of patients with UP‑NEN in a single institution. The medical records of four patients treated between November 2012 and January 2022 were retrospectively reviewed and clinical symptoms, diagnostic methods, image findings and treatment modalities were considered. All patients were diagnosed having functional UP‑NENs by using a short‑acting somatostatin test. These patients were treated with long‑acting release somatostatin analogs along with a positive result. Short‑acting somatostatin is an alternatively simple method to determine if a patient has UP‑NENs that are functional or expresses somatostatin receptors in the absence of imaging scanning.Keywords
This publication has 17 references indexed in Scilit:
- Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary SitesJournal of Clinical Oncology, 2016
- When should a liver resection be performed in patients with liver metastases from neuroendocrine tumours? A systematic review with practice recommendationsHPB, 2015
- A practical method to determine the site of unknown primary in metastatic neuroendocrine tumorsSurgery, 2014
- A 92-gene cancer classifier predicts the site of origin for neuroendocrine tumorsLaboratory Investigation, 2014
- Assigning Site of Origin in Metastatic Neuroendocrine NeoplasmsAdvances in Anatomic Pathology, 2013
- The Epidemiology of Neuroendocrine Tumors in Taiwan: A Nation-Wide Cancer Registry-Based StudyPLOS ONE, 2013
- ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown PrimaryNeuroendocrinology, 2012
- Long-term survival after surgical management of neuroendocrine hepatic metastasesHPB, 2010
- Neuroendocrine Carcinoma of Unknown Primary SiteSeminars in Oncology, 2009
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United StatesJournal of Clinical Oncology, 2008